cancer
Сүүлд шинэчилсэн: 2019-04-12

Ginza Phoenix клиник: Highly Active NK эс ба дархлааны хяналтын цэг хавсарсан эмчилгээ

S
Medical Supporter баг
Олон улсын эмнэлгийн зохицуулалт ба нийтлэлийн хяналтын баг
Ginza Phoenix клиник: Highly Active NK эс ба дархлааны хяналтын цэг хавсарсан эмчилгээ

Ginza Phoenix Clinic: Highly Active NK Cell and Immune Checkpoint Combined Therapy

Medical Supporter — Мэдээллийн мэдэгдэл

Энэ нийтлэл нь олон улсын эмнэлгийн мэдээллийн эмхэтгэл бөгөөд эмнэлгийн зөвлөгөө биш; таны эмчийн оношлогоо, эмчилгээний төлөвлөгөөг орлохгүй. Энд буй мэдээлэл нь Японы томоохон эмнэлгийн байгууллагуудын нээлттэй эх сурвалжаас эмхэтгэсэн бөгөөд аливаа эмчилгээний тохиромж, үр дүн өвчтөн бүрээр өөр тул мэргэшсэн эмч тус бүрчлэн үнэлэх ёстой.

Тодорхой эмчилгээний төлөвлөгөөг Японд лицензтэй эмч үнэлэх ёстой

Director ginzaDirector ginza

Located in the UDX Building in Chiyoda-ku, Tokyo, Ginza Phoenix Clinic is a high-end clinic specializing in regenerative medicine and immuno-oncology. Guided by Director Tetsuyuki Hirahata, the clinic is dedicated to applying advanced immune defense reconstruction technologies to anti-cancer practice.

NK Cell Combination with Immune Checkpoint Inhibitors: This is a core advantage. Based on the patient's condition, Opdivo or Keytruda is used with high-activity NK cells. This "combination therapy" unmasks cancer cells and boosts immune attacks, offering a new turning point for refractory cancers.

Core Features and Technologies

  1. Highly Active NK Cell Therapy: Holds Category II Regenerative Medicine certification from the MHLW. NK cells expanded through patented technology are significantly superior in both number and activity compared to traditional methods.
  2. Immune Checkpoint Inhibitor Combinations: Based on the patient's current condition, physicians flexibly use Opdivo (Nivolumab) or Keytruda (Pembrolizumab) in combination with cell therapy to achieve synergistic anti-cancer effects.
  3. Refined Personal Care: The clinic provides a quiet and private environment with detailed one-on-one consultations, allowing patients to receive advanced and warm nurturing care in a comfortable atmosphere.

【Medical Supporter Guardian Statement】 Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Японд эмчлүүлэхээр төлөвлөж байна уу? Мэдээлэл, тусламж хэрэгтэй юу?

Бид Японд эмчлүүлэхэд шаардлагатай мэдээллийг эмхэтгэх, Японы эмнэлгийн байгууллагуудтай холбогдох, хоёр дахь саналын зөвлөгөө зохион байгуулахад тусална.Анхны зөвлөгөө үнэгүй; зөвлөх таны дараагийн алхмыг тодорхой болгоход тусална.

Фукуока төв оффис: +81-92-409-5655
Өмнө нь албан ёсоор баталгаажсан, B-066 дугаар

Холбогдох уншлага

(уушгины хорт хавдар) нь Tagrisso Monotherapy үр дүнтэй?

The AURA3 Phase 3 clinical trial enrolled patients with EGFR T790M mutation-positive non-small cell lung cancer who had experienced disease progression following EGFR tyrosine kinase inhibitor treatment. Patients were randomized 2:1, with the primary endpoint of progression-fr...

2021-10-02

New Advances and Regulations for Opdivo (Nivolumab) in Malignant Melanoma Treatment

Ono Pharmaceutical of Japan has released the latest approval for Opdivo (Nivolumab) for patients with chemotherapy-naïve malignant melanoma. This article details clinical trial data (ONE-4538-08 and CA209-066) and latest usage dosages. As a Japanese medical visa guarantee inst...

2024-05-16

Matsukaze Naito эмнэлэг: Holistic хорт хавдар Care & Integrative эмнэлгийн Partner

Naito эмнэлэг нь dedicated руу providing comprehensive integrative эм. While pursuing physical recovery, it emphasizes psychological дэмжлэг ба mind-body balance, serving as чухал partner -д зориулсан Medical Supporter -д Fukuoka.

2022-06-14

(Lung Cancer) FDA Grants Accelerated Approval of Rybrevant for EGFR exon 20 insertion Mutation Patients

On May 21, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval of Rybrevant, a bispecific antibody targeting EGFR and MET receptors, for patients with specific non-small cell lung cancer. It is indicated for locally advanced or metastatic non-small c...

2024-10-26